Summary

In Situ Hybridization Market Growth & Trends

The global in situ hybridization market size is expected to reach USD 2.42 billion by 2030 and is set to expand at 6.9% CAGR from 2023 - 2030, according to a new report by Grand View Research, Inc. Situ Hybridization (ISH) is extensively utilized for research and clinical applications of diagnostics. ISH is a popular approach among researchers as it aids in determining the relationship between the distribution of specific nucleic acids and the target gene protein products. Hence, expanding the scope of ISH in applications is accelerating and leading to further research.

The increasing awareness about ISH techniques and their usage encourages researchers to employ the techniques for various applications. For instance, the CEO of MultiplexDX stated in an interview with Elsevier that FISH technology can contribute breakthrough information for early drug development and personalized treatment. A growing number of people in developed countries are opting for personalized treatment owing to an increase in awareness, thus boosting market demand.

Furthermore, reimbursement schemes being made available in developed economies have led to an increase in demand for this diagnosis. The demand continues to increase as the majority of the public can now afford it due to the recent expansion through insurance coverage. For instance, Medicare is the largest market player in the U.S., which provides care for those aged 65 years and above, irrespective of their income and medical history.

Owing to the COVID-19 pandemic, the demand side showcased a positive impact on the ISH market as various researchers employed the technique on COVID-19-infected cells. Research published in July 2020, considered 8 autopsy lungs, 10 kidney biopsies, and 1 placenta from COVID-19-infected patients with ISH assay and RNA probes.

COVID-19 positive results showed in all 8 lungs and the placenta by ISH, but not in the kidney samples. The assay showcases a sensitive and specific technique for detecting the virus from tissue samples. Similarly, Advanced Cell Diagnostics, Inc., introduced RNAscope technology to support COVID-19 research.

The growing strategic initiatives by the companies are anticipated to boost the ISH market growth. Key players are introducing novel products in the market to strengthen their portfolios. For instance, in March 2021, F. Hoffmann-La Roche launched DISCOVERY Green HRP chromogen detection kit to expand the multiplexing capability of in situ hybridization and immunohistochemistry.

On the other hand, molecular diagnostics renders accurate & effective results and has indispensable applications in the field of diagnosis. However, the high manufacturing cost of FISH assays and the high amount of capital required for specialized assembly plants & maintenance of instruments used in FISH imaging are likely to limit revenue generation.

In Situ Hybridization Market Report Highlights

• By technology, the CISH segment is projected to expand at the fastest growth rate during the forecast period. Since the reagents used in CISH are more stable, the sample can be stored for a longer duration and can be examined multiple times

• By probe, the DNA segment is anticipated to have the fastest growth rate during the forecast period. Owing to the increasing incidence of diseases associated with chromosomal aberrations, such as genetic abnormalities and cancer

• By product, the services segment is anticipated to have the fastest-growing CAGR between 2023 to 2030. Increasing outsourcing to ensure high adherence to quality standards and improve operational functionalities contributes to the lucrative growth

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Scope & Segment Definition
1.3.1 Technology
1.3.2 Probe
1.3.3 Product
1.3.4 End-Use
1.4 Market Model
1.4.1 Market Study, By Company Market Share
1.4.2 Regional Analysis
Chapter 2 Executive Summary
2.1 Market Snapshot, 2022
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation And Scope
3.2 Market Lineage Outlook
3.2.1 Parent Market Outlook
3.2.2 Related/Ancillary Market Outlook
3.3 Market Trends And Outlook
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Rising Prevalence Of Target Disorders
3.4.1.2 Technological Advancements In The Field Of In Vitro Diagnostics
3.4.1.3 Increasing R&D Investments In In Vitro Diagnostics
3.4.2 Market Restraint Analysis
3.4.2.1 High Cost Of ISH
3.4.2.2 Presence Of An Ambiguous Regulatory Framework
3.4.3 Market Opportunity Analysis
3.4.3.1 Increasing Awareness About The Ish Usage
3.4.4 Market Challenge Analysis
3.4.4.1 Highly Skilled Labour-Intensive Product
3.5 Penetration and Growth Prospect Mapping for Application 2022 (USD Million)
3.6 Business Environment Analysis
3.6.1 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2 Porter’s Five Forces Analysis
3.7 Covid-19 Impact Analysis:
3.7.1 Challenge Analysis
3.7.2 Opportunity Analysis
3.7.3 Key Developments And Activities
Chapter 4 Technology Type Business Analysis
4.1 In Situ Hybridization Market: Technology Movement Analysis
4.2 FISH
4.2.1 In Situ Hybridization Market For FISH, 2018 - 2030 (USD Million)
4.3 CISH
4.3.1 In Situ Hybridization Market For CISH, 2018 - 2030 (USD Million)
Chapter 5 Probe Business Analysis
5.1 In Situ Hybridization Market: Probe Movement Analysis
5.2 DNA
5.2.1 In Situ Hybridization Market For DNA 2018 - 2030 (USD Million)
5.3 RNA
5.3.1 In Situ Hybridization Market For RNA 2018 - 2030 (USD Million)
Chapter 6 Product Business Analysis
6.1 In Situ Hybridization Market: Product Movement Analysis
6.2 Instruments
6.2.1 In Situ Hybridization Market For Instruments, 2018 - 2030 (USD Million)
6.3 Kits And Probes
6.3.1 In Situ Hybridization Market For Kits And Probes, 2018 - 2030 (USD Million)
6.4 Software
6.4.1 In Situ Hybridization Market For Software, 2018 - 2030 (USD Million)
6.5 Services
6.5.1 In Situ Hybridization Market For Services, 2018 - 2030 (USD Million)
Chapter 7 Application Business Analysis
7.1 In Situ Hybridization Market: Application Movement Analysis
7.2 Cancer
7.2.1 Cancer Application For In Situ Hybridization Market, 2018 - 2030 (USD Million)
7.3 Cytogenetics
7.3.1 Cytogenetics Application For In Situ Hybridization Market, 2018 - 2030 (USD Million)
7.4 Developmental Biology
7.4.1 Development Biology Application For In Situ Hybridization Market, 2018 - 2030 (USD Million)
7.5 Infectious Diseases
7.5.1 Infectious Diseases Application For In Situ Hybridization Market, 2018 - 2030 (USD Million)
7.6 Others
7.6.1 Other Applications For In Situ Hybridization Market, 2018 - 2030 (USD Million)
Chapter 8 End-Use Type Business Analysis
8.1 In Situ Hybridization Market: End-Use Movement Analysis
8.2 Hospital & Diagnostics Laboratories
8.2.1 In Situ Hybridization Market For Hospital & Diagnostics Laboratories, 2018 - 2030 (USD Million)
8.3 CROs
8.3.1 In Situ Hybridization Market For CROs, 2018 - 2030 (USD Million)
8.4 Academic Institutes
8.4.1 In Situ Hybridization Market For Academic Institutes, 2018 - 2030 (USD Million)
8.5 Others
8.5.1 In Situ Hybridization Market For Other, 2018 - 2030 (USD Million)
Chapter 9 Regional Business Analysis
9.1 In Situ Hybridization Market Share By Region, 2022 & 2030
9.2 North America
9.2.1 Swot Analysis
9.2.1.1 North America In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.2.1.2 North America In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.2.1.3 North America In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.2.1.4 North America In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.2.1.5 North America In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 Target Disease Prevalence
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.2.6 U.S. In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.2.2.7 U.S. In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.2.2.8 U.S. In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.2.2.9 U.S. In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.2.2.10 U.S. In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Target Disease Prevalence
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.2.3.6 Canada In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.2.3.7 Canada In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.2.3.8 Canada In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.2.3.9 Canada In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.2.3.10 Canada In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3 Europe
9.3.1 Swot Analysis
9.3.1.1 Europe In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.1.2 Europe In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.1.3 Europe In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.1.4 Europe In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.1.5 Europe In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3.2 Germany
9.3.2.1 Key Country Dynamics
9.3.2.2 Target Disease Prevalence
9.3.2.3 Competitive Scenario
9.3.2.4 Regulatory Framework
9.3.2.5 Reimbursement Scenario
9.3.2.6 Germany In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.2.7 Germany In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.2.8 Germany In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.2.9 Germany In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.2.10 Germany In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3.3 U.K.
9.3.3.1 Key Country Dynamics
9.3.3.2 Target Disease Prevalence
9.3.3.3 Competitive Scenario
9.3.3.4 Regulatory Framework
9.3.3.5 Reimbursement Scenario
9.3.3.6 U.K. In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.3.7 U.K. In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.3.8 U.K. In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.3.9 U.K. In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.3.10 U.K. In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3.4 France
9.3.4.1 Key Country Dynamics
9.3.4.2 Target Disease Prevalence
9.3.4.3 Competitive Scenario
9.3.4.4 Regulatory Framework
9.3.4.5 Reimbursement Scenario
9.3.4.6 France In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.4.7 France In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.4.8 France In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.4.9 France In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.4.10 France In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3.5 Italy
9.3.5.1 Key Country Dynamics
9.3.5.2 Target Disease Prevalence
9.3.5.3 Competitive Scenario
9.3.5.4 Regulatory Framework
9.3.5.5 Reimbursement Scenario
9.3.5.6 Italy In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.5.7 Italy In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.5.8 Italy In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.5.9 Italy In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.5.10 Italy In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3.6 Spain
9.3.6.1 Key Country Dynamics
9.3.6.2 Target Disease Prevalence
9.3.6.3 Competitive Scenario
9.3.6.4 Regulatory Framework
9.3.6.5 Reimbursement Scenario
9.3.6.6 Spain In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.6.7 Spain In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.6.8 Spain In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.6.9 Spain In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.6.10 Spain In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3.7 Denmark
9.3.7.1 Key Country Dynamics
9.3.7.2 Target Disease Prevalence
9.3.7.3 Competitive Scenario
9.3.7.4 Regulatory Framework
9.3.7.5 Reimbursement Scenario
9.3.7.6 Denmark In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.7.7 Denmark In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.7.8 Denmark In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.7.9 Denmark In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.7.10 Denmark In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3.9 Sweden
9.3.8.1 Key Country Dynamics
9.3.8.2 Target Disease Prevalence
9.3.8.3 Competitive Scenario
9.3.8.4 Regulatory Framework
9.3.8.5 Reimbursement Scenario
9.3.8.6 Sweden In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.8.7 Sweden In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.8.8 Sweden In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.8.9 Sweden In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.8.10 Sweden In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.3.9 Norway
9.3.9.1 Key Country Dynamics
9.3.9.2 Target Disease Prevalence
9.3.9.3 Competitive Scenario
9.3.9.4 Regulatory Framework
9.3.9.5 Reimbursement Scenario
9.3.9.6 Norway In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.3.9.7 Norway In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.3.9.8 Norway In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.3.9.9 Norway In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.3.9.10 Norway In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.4 Asia Pacific
9.4.1 Swot Analysis
9.4.1.1 Asia Pacific In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.4.1.2 Asia Pacific In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.4.1.3 Asia Pacific In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.4.1.4 Asia Pacific In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.4.1.5 Asia Pacific In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Key Country Dynamics
9.4.2.2 Target Disease Prevalence
9.4.2.3 Competitive Scenario
9.4.2.4 Regulatory Framework
9.4.2.5 Reimbursement Scenario
9.4.2.6 Japan In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.4.2.7 Japan In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.4.2.8 Japan In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.4.2.9 Japan In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.4.2.10 Japan In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.4.3 China
9.4.3.1 Key Country Dynamics
9.4.3.2 Target Disease Prevalence
9.4.3.3 Competitive Scenario
9.4.3.4 Regulatory Framework
9.4.3.5 Reimbursement Scenario
9.4.3.6 China In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.4.3.7 China In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.4.3.8 China In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.4.3.9 China In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.4.3.10 China In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.4.4 India
9.4.4.1 Key Country Dynamics
9.4.4.2 Target Disease Prevalence
9.4.4.3 Competitive Scenario
9.4.4.4 Regulatory Framework
9.4.4.5 Reimbursement Scenario
9.4.4.6 India In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.4.4.7 India In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.4.4.8 India In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.4.4.9 India In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.4.4.10 India In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.4.5 South Korea
9.4.5.1 Key Country Dynamics
9.4.5.2 Target Disease Prevalence
9.4.5.3 Competitive Scenario
9.4.5.4 Regulatory Framework
9.4.5.5 Reimbursement Scenario
9.4.5.6 South Korea In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.4.5.7 South Korea In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.4.5.8 South Korea In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.4.5.9 South Korea In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.4.5.10 South Korea In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.4.6 Australia
9.3.9.1 Key Country Dynamics
9.4.6.2 Target Disease Prevalence
9.4.6.3 Competitive Scenario
9.4.6.4 Regulatory Framework
9.4.6.5 Reimbursement Scenario
9.4.6.6 Australia In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.4.6.7 Australia In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.4.6.8 Australia In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.4.6.9 Australia In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.4.6.10 Australia In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.4.7 Thailand
9.4.7.1 Key Country Dynamics
9.4.7.2 Target Disease Prevalence
9.4.7.3 Competitive Scenario
9.4.7.4 Regulatory Framework
9.4.7.5 Reimbursement Scenario
9.4.7.6 Thailand In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.4.7.7 Thailand In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.4.7.8 Thailand In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.4.7.9 Thailand In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.4.7.10 Thailand In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.5 Latin America
9.5.1 Swot Analysis
9.5.1.1 Latin America In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.5.1.2 Latin America In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.5.1.3 Latin America In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.5.1.4 Latin America In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.5.1.5 Latin America In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Key Country Dynamics
9.5.2.2 Target Disease Prevalence
9.5.2.3 Competitive Scenario
9.5.2.4 Regulatory Framework
9.5.2.5 Reimbursement Scenario
9.5.2.6 Brazil In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.5.2.7 Brazil In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.5.2.8 Brazil In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.5.2.9 Brazil In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.5.2.10 Brazil In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.5.3 Mexico
9.5.3.1 Key Country Dynamics
9.5.3.2 Target Disease Prevalence
9.5.3.3 Competitive Scenario
9.5.3.4 Regulatory Framework
9.5.3.5 Reimbursement Scenario
9.5.3.6 Mexico In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.5.3.7 Mexico In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.5.3.8 Mexico In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.5.3.9 Mexico In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.5.3.10 Mexico In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.5.4 Argentina
9.5.4.1 Key Country Dynamics
9.5.4.2 Target Disease Prevalence
9.5.4.3 Competitive Scenario
9.5.4.4 Regulatory Framework
9.5.4.5 Reimbursement Scenario
9.5.4.6 Argentina In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.5.4.7 Argentina In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.5.4.8 Argentina In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.5.4.9 Argentina In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.5.4.10 Argentina In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.6 MEA
9.6.1 Swot Analysis
9.6.1.1 MEA In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.6.1.2 MEA In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.6.1.3 MEA In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.6.1.4 MEA In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.6.1.5 MEA In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.6.2 South Africa
9.6.2.1 Key Country Dynamics
9.6.2.2 Target Disease Prevalence
9.6.2.3 Competitive Scenario
9.6.2.4 Regulatory Framework
9.6.2.5 Reimbursement Scenario
9.6.2.6 South Africa In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.6.2.7 South Africa In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.6.2.8 South Africa In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.6.2.9 South Africa In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.6.2.10 South Africa In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.6.3 Saudi Arabia
9.6.3.1 Key Country Dynamics
9.6.3.2 Target Disease Prevalence
9.6.3.3 Competitive Scenario
9.6.3.4 Regulatory Framework
9.6.3.5 Reimbursement Scenario
9.6.3.6 Saudi Arabia In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.6.3.7 Saudi Arabia In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.6.3.8 Saudi Arabia In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.6.3.9 Saudi Arabia In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.6.3.10 Saudi Arabia In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.6.4 UAE
9.6.4.1 Key Country Dynamics
9.6.4.2 Target Disease Prevalence
9.6.4.3 Competitive Scenario
9.6.4.4 Regulatory Framework
9.6.4.5 Reimbursement Scenario
9.6.4.6 UAE In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.6.4.7 UAE In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.6.4.8 UAE In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.6.4.9 UAE In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.6.4.10 UAE In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
9.6.5 Kuwait
9.6.5.1 Key Country Dynamics
9.6.5.2 Target Disease Prevalence
9.6.5.3 Competitive Scenario
9.6.5.4 Regulatory Framework
9.6.5.5 Reimbursement Scenario
9.6.5.6 Kuwait In Situ Hybridization (ISH) Market, By Technology, 2018 - 2030 (USD Million)
9.6.5.7 Kuwait In Situ Hybridization (ISH) Market, By Probe, 2018 - 2030 (USD Million)
9.6.5.8 Kuwait In Situ Hybridization (ISH) Market, By Product, 2018 - 2030 (USD Million)
9.6.5.9 Kuwait In Situ Hybridization (ISH) Market, By Application, 2018 - 2030 (USD Million)
9.6.5.10 Kuwait In Situ Hybridization (ISH) Market, By End-Use, 2018 - 2030 (USD Million)
Chapter 10 Competitive Landscape
10.1 Participant’s Overview
10.2 Financial Performance
10.3 Participant Categorization
10.3.1 Market Leaders
10.3.1.1 In Situ Hybridization Market Share Analysis, 2022
10.3.1.2 Company Profiles
10.3.1.2.1 Thermo Fisher Scientific Inc.
10.3.1.2.2 Abbott (Abbott Molecular)
10.3.1.2.3 Perkinelmer, Inc.
10.3.1.2.4 Bioview
10.3.1.2.5 Agilent Technologies, Inc.
10.3.1.2.6 Merck Kgaa
10.3.1.2.7 Bio-Rad Laboratories, Inc.
10.3.1.2.8 Oxford Gene Technology Ip Limited
10.3.1.2.9 Leica Biosystems Nussloch Gmbh
10.3.1.2.10 F. Hoffman-La Roche Limited
10.3.1.2.11 Neogenomics Laboratories, Inc.